NSAID (83, 9% med abatacept, 85, 1% med placebo); systemiske kortikosteroider (74, 7% med abatacept, 75, 8% med placebo); non- biologisk DMARD- behandling, hyppigst chloroquin/ hydroxychloroquin, leflunomid og/ eller sulfasalazin (26, 9% med abatacept, 32, 1% med placebo); TNF- hæmmende midler, primært etanercept, (9, 4% med abatacept, 12, 3% med placebo) og anakinra (1, 1% med abatacept, 1, 6% med placebo).
NSAIDs (83.9% with abatacept, 85.1% with placebo); systemic corticosteroids (74.7% with abatacept, 75.8% with placebo); non-biological DMARD therapy, most commonly chloroquine/ hydroxychloroquine, leflunomide and/ or sulfasalazine (26.9% with abatacept, 32.1% with placebo); TNF blocking agents, mainly etanercept (9.4% with abatacept, 12.3% with placebo); and anakinra (1.1% with abatacept, 1.6% with placebo).